Joseph Shows, MD
Hematology & Oncology · Baton Rouge, LANPI 1972795250
Payments from drug & device makers
Across 179 payments — averaging $286.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Global Blood Therapeutics, Inc.$27K
- Pfizer$21K
- Bristol Myers Squibb$472
- Novartis$438
- AbbVie$181
- Medtronic$150
- plus $1K from 27 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Global Blood Therapeutics, Inc. | 26 | $27,282 |
| Pfizer | 35 | $21,367 |
| Bristol Myers Squibb | 21 | $472 |
| Novartis | 26 | $438 |
| AbbVie | 6 | $181 |
| Medtronic | 1 | $150 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $143 |
| Gilead | 7 | $128 |
| Merck | 5 | $97 |
| Daiichi Sankyo Inc. | 4 | $90 |
| Amgen | 2 | $89 |
| Array Biopharma Inc | 4 | $83 |
| Veracyte, Inc. | 3 | $72 |
| Blueprint Medicines Corporation | 4 | $69 |
| Incyte Corporation | 3 | $64 |
| Astellas Pharma US Inc | 2 | $53 |
| AstraZeneca | 3 | $52 |
| Johnson & Johnson | 3 | $48 |
| G1 Therapeutics, Inc. | 3 | $47 |
| Progenics Pharmaceuticals, Inc. | 1 | $46 |
| CTI Biopharma Corp. | 2 | $36 |
| Dendreon Pharmaceuticals LLC | 2 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $32 |
| Menarini Silicon Biosystems, Inc. | 1 | $22 |
| Sanofi | 1 | $19 |
| Tempus AI, Inc | 1 | $19 |
| Seagen Inc. | 1 | $17 |
| Beigene USA, Inc. | 1 | $17 |
| Recordati_rare_diseases_inc. | 1 | $16 |
| Agios Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Rigel Pharmaceuticals, Inc. | 1 | $10 |
How this compares
$51,238 in reported general payments places this provider in the 70th percentile of 183 hematology & oncology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Baton Rouge
- Hana SafahBaton Rouge$3.8M
- Nakhle SabaBaton Rouge$2.4M
- Victor LinBaton Rouge$2.3M
- Marshall StaggBaton Rouge$1.6M
- William VarnadoBaton Rouge$648K
- Andrew DalovisioBaton Rouge$389K
- Sobia OzairBaton Rouge$378K
- Sanjay JunejaBaton Rouge$346K
- Derrick SpellBaton Rouge$128K
- Christopher McCanlessBaton Rouge$80K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.